FACTIVE (gemifloxacin mesylate) by LG Chem Life Sciences is clinical pharmacology pharmacokinetics the pharmacokinetics of gemifloxacin are approximately linear over the dose range from 40 mg to 640 mg. Approved for infections caused by susceptible strains of the designated microorganisms in the conditions listed below, development of drug-resistant bacteria, maintain the effectiveness of factive and 3 more indications. First approved in 2003.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
FACTIVE (gemifloxacin mesylate) is an oral fluoroquinolone antibiotic that treats respiratory and urinary tract infections caused by susceptible bacteria. It works by inhibiting bacterial DNA gyrase and topoisomerase IV, leading to rapid bacterial cell death. The drug is rapidly absorbed orally with peak plasma concentrations achieved within 0.5-2 hours and achieves steady-state by day three of dosing.
Product is in late-stage lifecycle with minimal linked career opportunities; teams are likely transitioning toward lifecycle management and cost containment strategies rather than growth initiatives.
CLINICAL PHARMACOLOGY Pharmacokinetics The pharmacokinetics of gemifloxacin are approximately linear over the dose range from 40 mg to 640 mg. There was minimal accumulation of gemifloxacin following multiple oral doses up to 640 mg a day for 7 days (mean accumulation <20%). Following repeat oral…
Worked on FACTIVE at LG Chem Life Sciences? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on FACTIVE offers limited career growth due to LOE-approaching lifecycle status and minimal linked job openings (0 identified). Roles available focus on managed decline, generic preparation, and market-access strategy rather than innovation or expansion. This is a consolidation or wind-down opportunity best suited for those seeking stable, process-driven work in a mature product environment.